241 related articles for article (PubMed ID: 38697125)
1. NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors.
Wang Y; Liu X; Zuo X; Wang C; Zhang Z; Zhang H; Zeng T; Chen S; Liu M; Chen H; Song Q; Li Q; Yang C; Le Y; Xing J; Zhang H; An J; Jia W; Kang L; Zhang H; Xie H; Ye J; Wu T; He F; Zhang X; Li Y; Zhou G
Cell Genom; 2024 May; 4(5):100550. PubMed ID: 38697125
[TBL] [Abstract][Full Text] [Related]
2. Rare-variant association study unveils the Achilles' heel for HCC.
Wang Y; Chan YW
Cell Genom; 2024 May; 4(5):100558. PubMed ID: 38723605
[TBL] [Abstract][Full Text] [Related]
3. Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
Cao K; Wang R; Li L; Liao Y; Hu X; Li R; Liu X; Xiong XD; Wang Y; Liu X
Oncogene; 2024 Jan; 43(1):35-46. PubMed ID: 38007537
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors.
Funato K; Otsuka M; Sekiba K; Miyakawa Y; Seimiya T; Shibata C; Kishikawa T; Fujishiro M
Biochem Biophys Res Commun; 2022 Jun; 607():89-95. PubMed ID: 35367833
[TBL] [Abstract][Full Text] [Related]
5. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
6. Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
Zai W; Chen W; Han Y; Wu Z; Fan J; Zhang X; Luan J; Tang S; Jin X; Fu X; Gao H; Ju D; Liu H
Carcinogenesis; 2020 May; 41(3):345-357. PubMed ID: 31175354
[TBL] [Abstract][Full Text] [Related]
7. NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition.
Bishara LA; Machour FE; Awwad SW; Ayoub N
DNA Repair (Amst); 2021 Jan; 97():103025. PubMed ID: 33248388
[TBL] [Abstract][Full Text] [Related]
8. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
9. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Zhang JX; Li DQ; He AR; Motwani M; Vasiliou V; Eswaran J; Mishra L; Kumar R
Hepatology; 2012 Jun; 55(6):1840-51. PubMed ID: 22223166
[TBL] [Abstract][Full Text] [Related]
11. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
[TBL] [Abstract][Full Text] [Related]
12. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
13. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
14. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.
Zhang S; Peng X; Li X; Liu H; Zhao B; Elkabets M; Liu Y; Wang W; Wang R; Zhong Y; Kong D
Cell Death Dis; 2021 May; 12(6):546. PubMed ID: 34039959
[TBL] [Abstract][Full Text] [Related]
15. Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy.
Zhang L; Peng Y; Uray IP; Shen J; Wang L; Peng X; Brown PH; Tu W; Peng G
DNA Repair (Amst); 2017 Dec; 60():89-101. PubMed ID: 29112893
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism.
Wu J; Yan J; Fang P; Zhou HB; Liang K; Huang J
Cancer Lett; 2020 Jan; 469():78-88. PubMed ID: 31629931
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Chen L; Hou J; Zeng X; Guo Q; Deng M; Kloeber JA; Tu X; Zhao F; Wu Z; Huang J; Luo K; Kim W; Lou Z
Clin Transl Med; 2021 Mar; 11(3):e341. PubMed ID: 33784003
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine.
Lee WP; Tai DI; Tsai SL; Yeh CT; Chao Y; Lee SD; Hung MC
Cancer Res; 2003 Oct; 63(19):6229-36. PubMed ID: 14559808
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
20. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]